Reuters in a post has said Strides Pharma Science Ltd has got the regulatory approval to conduct clinical trials of antiviral drug favipiravir, considered a potential treatment for COVID-19.
Strides has received approval from the Drug Controller General of India to conduct trials of favipiravir in the country, Strides Founder and Non-Executive Chairman Arun Kumar said on a post-earnings conference call, without giving any more details.
Favipiravir is manufactured under the brand name Avigan by a unit of Japan’s Fujifilm Holdings Corp and was approved for use as an anti-flu drug in the country in 2014.
Source & Credit: Reuters

Strides has received approval from the Drug Controller General of India to conduct trials of favipiravir in the country.